Medtronic touts the study as the longest patient follow-up data ever for U.S. 2-level cervical disc patients. The data was presented at the 84th Annual Meeting of the American Association of Neurological Surgeons in Chicago this week.
“This is the longest follow-up data available on clinical study patients treated with 2-level cervical arthroplasty in the United States. We’re committed to developing meaningful innovations – like the Prestige LP Disc – that fundamentally change patients’ lives. That’s why it’s exciting to see that the patients treated with the Prestige LP Disc maintain their outcomes for 7 years,” spine division R&D veep Tommy Carls said in a prepared release.
The Prestige LP disc is indicated for single-level cervical disc disease and is designed to preserve motion in the neck, unlike fusion surgery procedures that do not allow such motion, Fridley, Minn.-based Medtronic said.
Data from the 397-patient study indicated a 78.6% overall success rate for Prestige patients compared to a 62.7% rate in patients treated with 2-level ACDF.
Medtronic touted a 91.6% rate of neurological success with the Prestige, compared to 82.1% in the control group, as well as an 87% rate of patient-reported outcomes through the Neck Disability Index, compared to 82.1% with 2-level ACDF.
Second surgeries were lower with the Prestige implant at 4.2% comapred to 14.7%, while adverse event profiles were similar between groups.
“The 7-year results of this study show that the patients receiving 2-level cervical disc replacement exhibited beneficial clinical outcomes and maintained them over timeAt 84 months, the patients treated with the 2-level Prestige LP Disc demonstrated greater rates of overall success compared to the 2-level ACDF patients,” Dr. Todd Lanman of Los Angeles’ Cedar-Sinai Institute for Spinal Disorders said in a press release.